Parallax Volatility Advisers, L.P. Seagen Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $4.63 Million - $5.23 Million	24,200 Added 30.79%	102,800 $21.8 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $4.02 Million - $4.41 Million	21,400 Added 37.41%	78,600 $15.1 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $5.31 Million - $8.45 Million	41,600 Added 266.67%	57,200 $11.6 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $58,685 - $69,585	500 Added 3.31%	15,600 $2 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $2.04 Million - $2.72 Million	15,100 New	15,100 $2.07 Million
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $533,169 - $878,717	-4,900 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $586,089 - $773,465	4,900 New	4,900 $706,000
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $99,799 - $133,602	700 Added 116.67%	1,300 $200,000
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $185,341 - $248,118	-1,300 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $85,470 - $101,892	600 New	600 $102,000
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $2.14 Million - $2.55 Million	-15,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $2.03 Million - $2.42 Million	15,000 New	15,000 $2.37 Million
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $550,040 - $763,200	-4,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $1.98 Million - $2.75 Million	-14,400 Reduced 78.26%	4,000 $556,000
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $3.03 Million - $3.9 Million	18,400 New	18,400 $3.23 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.